Received Feb 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPHEPBIP | DTAP + HEPB + IPV (PEDIARIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | BY247 | IM / LL |
patient received an expired dose; This non-serious case was reported by a consumer via call center representative and described the occurrence of expired vaccine used in a 9-week-old female patient who received DTPa-HBV-IPV (Pediarix) (batch number BY247, expiry date 17-NOV-2023) for prophylaxis. On 21-DEC-2023, the patient received the 1st dose of Pediarix (intramuscular, left thigh) .5 ml. On 21-DEC-2023, an unknown time after receiving Pediarix, the patient experienced expired vaccine used (Verbatim: patient received an expired dose). The outcome of the expired vaccine used was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 28-JAN-2025 The reporter states that the patient received her first dose of Pediarix on 21-DEC-2023, and the reporter just found out from the patient's new clinic, that the patient received an expired dose, which led to expired vaccine used. The reporter stated that the nurse that administered the dose no longer works at the clinic. The patient also received her first two month dose on 21-DEC-2023, six days past 8 weeks of age, the second four month dose on 26-FEB-2024, one day past four months of age, and the third six month dose on 26-APR-2024, eleven days past six months of age.